Core Viewpoint - Robbins LLP has announced a class action lawsuit against Vital Farms, Inc. for allegedly misleading investors regarding its business prospects during the period from May 8, 2025, to February 26, 2026 [1][2]. Allegations - The lawsuit claims that Vital Farms made false and misleading statements about the implementation of an enterprise resource planning (ERP) system, which was said to be crucial for operational improvements [2]. - Defendants allegedly did not disclose that the ERP implementation would lead to delays in shipments and production, which could negatively impact the company's business [2]. - The complaint highlights that management was aware of potential issues surrounding the ERP implementation but failed to adequately inform investors [2]. Financial Performance - On February 26, 2026, Vital Farms reported its fiscal year 2025 revenue at $759.44 million, which was below the guidance of $775 million [3]. - The company also reported earnings per share (EPS) of $0.35, missing the market consensus of $0.39 [3]. - Following the release of this information, Vital Farms' stock price fell by $2.68, or 10.8%, closing at $22.11 [3]. Class Action Participation - Shareholders who purchased Vital Farms securities during the specified period may be eligible to participate in the class action lawsuit [4]. - Interested parties can contact Robbins LLP to serve as lead plaintiff or to receive further information [4]. Company Background - Vital Farms is recognized as a leading U.S. brand of pasture-raised eggs and the second-largest U.S. egg brand by retail dollar sales [1].

Core Viewpoint - A class action lawsuit has been filed against Lufax Holding Ltd. for securities fraud, affecting investors who purchased shares between April 7, 2023, and January 26, 2025, with a deadline for lead plaintiff motions set for May 20, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that Lufax made materially false and misleading statements and failed to disclose adverse facts about its business and financial condition during the class period [4]. - Lufax's stock price dropped by $0.40, or 13.8%, to close at $2.49 per share on January 27, 2025, following the announcement of concerns from its auditor, PricewaterhouseCoopers (PwC) [3]. - On February 17, 2025, Lufax confirmed that its 2022 and 2023 financial reports were unreliable, revealing material net profit declines from previously issued reports [4]. Group 2: Financial Disclosures - The lawsuit highlights that Lufax lacked adequate internal controls and that certain financial results were materially misstated, leading to misleading positive statements about the company's operations and prospects [4]. - The 2024 Annual Report provided restated net profit figures, indicating significant discrepancies from earlier reports [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hitek Global Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is focused on potential civil securities claims against Hitek Global Inc. [3]. - Shareholders who purchased Hitek securities may be entitled to compensation through a class action without any out-of-pocket fees [2]. Group 2: Class Action Information - Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Hitek Global Inc. [2]. - Interested parties can join the prospective class action by visiting the provided link or contacting the firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Coty Inc. is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its growth prospects and financial performance during the fiscal year 2026 [5]. Group 1: Lawsuit Details - The Schall Law Firm is leading the class action lawsuit against Coty Inc. for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Coty securities between November 5, 2025, and February 4, 2026, are encouraged to participate in the lawsuit before the deadline of May 22, 2026 [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [4]. Group 2: Allegations Against Coty - The lawsuit claims that Coty made overwhelmingly positive statements about its growth prospects, despite evidence of slowing growth and underperformance in its Consumer Beauty segment [5]. - The company's increasing marketing expenditures are said to negatively impact its profit margins, contributing to the misleading nature of its public statements [5]. - Investors reportedly suffered damages when the market became aware of the true state of Coty's financial performance [5].

Core Viewpoint - ODDITY Tech Ltd. is facing a securities fraud lawsuit due to significant financial losses attributed to issues with its largest advertising partner, leading to a drastic decline in stock price and expected revenue [2][3]. Financial Performance - On February 25, 2026, ODDITY reported a 30% year-over-year decline in expected revenue for Q1 2026, primarily due to increased user acquisition costs resulting from algorithm changes by its largest advertising partner [2][3]. Stock Market Reaction - Following the financial disclosure, ODDITY's stock price plummeted by $14.28, or 49.2%, closing at $14.74 per share on February 25, 2026, which significantly impacted investors [3]. Lawsuit Details - The class action lawsuit alleges that ODDITY's management made materially false and misleading statements regarding the company's business operations and financial health, failing to disclose the adverse effects of the advertising partner's algorithm changes [3][4].

Core Viewpoint - Atara Biotherapeutics, Inc. is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its product tabelecleucel and associated manufacturing issues [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Atara Biotherapeutics for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Atara's securities between May 20, 2024, and January 9, 2026, are encouraged to participate in the lawsuit before May 22, 2026 [2]. - The lawsuit claims that Atara made false statements about its manufacturing capabilities and the likelihood of FDA approval for tabelecleucel, leading to investor losses when the truth was revealed [4]. Group 2: Company Issues - Atara is reported to have faced significant manufacturing problems and deficiencies in its ALLELE study, which raised concerns about regulatory approval [4]. - The company allegedly overstated the prospects of its product tabelecleucel, which contributed to the misleading public statements [4]. - The lawsuit indicates that Atara's public statements were materially misleading throughout the class period, resulting in damages to investors when the actual situation became known [4].

Core Viewpoint - Hercules Capital, Inc. is facing a class action lawsuit for securities fraud, with allegations of misleading investors regarding its loan origination process and portfolio valuation [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Hercules Capital, Inc. for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Hercules securities between May 1, 2025, and February 27, 2026, are encouraged to participate in the lawsuit [2]. - The lawsuit claims that Hercules made false and misleading statements about its due diligence and portfolio investments, leading to investor losses when the truth was revealed [4]. Group 2: Investor Participation - Investors are urged to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3]. - The class for the lawsuit has not yet been certified, meaning that investors are not currently represented by an attorney unless they take action [3]. Group 3: Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5].

Core Viewpoint - Halper Sadeh LLC is investigating whether Terns Pharmaceuticals, Inc. is obtaining a fair price for its shareholders in the proposed sale to Merck for $53.00 per share in cash [2][4]. Group 1: Investigation Details - The investigation focuses on potential violations of federal securities laws and breaches of fiduciary duties by Terns and its board, including failing to secure the best possible price for shareholders and not conducting a fair sales process [4]. - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits for Terns shareholders [4]. Group 2: Shareholder Rights - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options at no cost or obligation, with legal fees handled on a contingent fee basis [2][3].

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against TruBridge, Inc. due to possible violations of federal securities laws or unlawful business practices by the company and/or its senior management [1]. Group 1: Investigation Details - On March 16, 2026, TruBridge announced it would not be able to file its 2025 Annual Report on time due to identified errors in its consolidated financial statements for the year ended December 31, 2024, as well as out-of-period errors in the condensed financial statements for the quarters ended March 31, June 30, and September 30, 2025 [2]. - The majority of the identified errors relate to accounting for revenue, software development costs, and share-based payments [2]. - Following this announcement, TruBridge's share price fell by $1.84, or approximately 10.5%, from $17.59 on March 16, 2026, to close at $15.75 on March 17, 2026 [2]. Group 2: Next Steps for Investors - Currently, no lawsuit has been filed, and the investigation is ongoing to determine if claims can be brought under federal securities laws [3]. - Investors who purchased or acquired TruBridge securities and have information or wish to learn more about the investigation are encouraged to contact Kirby McInerney LLP [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Concorde International Group, Ltd. (CIGL) and reminds investors of the May 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [2][4]. Group 1: Allegations Against Concorde International - The complaint alleges that Concorde and its executives violated federal securities laws by making false and misleading statements and failing to disclose critical information regarding a fraudulent stock promotion scheme [4]. - Specific allegations include the use of social media misinformation, insider trading through offshore accounts, and omission of artificial trading activity that inflated stock prices [4]. - The company's shares rose from an IPO price of $4.00 to a high of $31.06 in the weeks leading up to July 2025, despite no fundamental business developments justifying this increase [5]. Group 2: Impact on Investors - Investors learned the truth on July 10, 2025, when Concorde's share price collapsed approximately 80%, falling to $5.66 per share, and has since continued to decline to around $2.00 per share [6]. - The firm encourages investors who suffered losses to contact them directly to discuss their legal rights and options [1][9].